UroGen Pharma Ltd
Research UroGen Pharma Ltd (URGN) on Bullrun: market cap USD 1.76B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerURGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.76B
- Financial periodFY2025
- RevenueUSD 109.79M
- Revenue growth21.4%
- Net income-USD 153.49M
- Free cash flow-USD 162.73M
- Gross margin88.7%
Valuation Snapshot
latest market cap is USD 1.76B.
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor;
Frequently asked questions
What is UroGen Pharma Ltd's market cap?
UroGen Pharma Ltd's market capitalization is USD 1.76B.
What does UroGen Pharma Ltd do?
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology;